Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses
September 2019
Dr Chad Johannes DVM, Diplomate ACVIM (SAIM, Oncology) presented the tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results at two recent prestigious international congresses: European Society of Veterinary Oncology (ESVONC) and American College of Veterinary Internal Medicine Forum (ACVIM).
The clinical trial results of 75% Complete Response (full tumour destruction) with a single injection was enthusiastically received by the audiences at both conferences, which consisted of a mix of oncologists and general practitioner veterinarians.
Publications:
Wiest M. Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors. Presentation at American College of Veterinary Internal Medicine, June 2019
Wiest M. Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors. Presentation at European Society of Veterinary Oncology, May 2019